- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07376005
Effects of Acute Sugar Intake on Choroidal Thickness
January 21, 2026 updated by: Southern College of Optometry
This study aims to bridge that gap by investigating how acute sugar intake influences choroidal thickness.
Study Overview
Detailed Description
This investigation will be a prospective, repeated-measures study.
All subjects will arrive fasted and will be asked not to consume any outside food or beverages during the three-hour study period, and will be asked to abstain from caffeine intake for 12 hours before participation.
A baseline OCT scan of the macula of the right eye will be performed using the Heidelberg Spectralis OCT system.
Participants will then consume 30 grams of sugar in the form of glucose tablets.
Macular OCT scans of the right eye will be repeated every 30 minutes for 3 hours following sugar consumption.
Study Type
Interventional
Enrollment (Estimated)
47
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Morgan Ollinger, OD, MS
- Phone Number: 9017223377
- Email: mollinger@sco.edu
Study Locations
-
-
Tennessee
-
Memphis, Tennessee, United States, 38111
- Recruiting
- Southern College of Optometry
-
Contact:
- Morgan Ollinger, OD, MS
- Phone Number: 9017223377
- Email: mollinger@sco.edu
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- In order to be eligible for enrolment, each subject must have less than 6 diopters of spherical equivalent refractive error, and have no existing diagnosis of diabetes or pre-diabetes.
Exclusion Criteria:
- Any potential subject with known retinal pathology will be excluded. Any potential subject with any other known systemic or ocular conditions that may impact their ability to participate in the study or provide generalizable data will also be excluded.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Oral glucose
Subjects receive 30g of oral glucose
|
Participants will consume 30 grams of sugar in the form of glucose tablets.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in choroidal thickness
Time Frame: within 3 hours of baseline
|
The primary outcome for this investigation will be changes in choroidal thickness from baseline across timepoints.
|
within 3 hours of baseline
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
January 1, 2026
Primary Completion (Estimated)
May 1, 2026
Study Completion (Estimated)
May 1, 2026
Study Registration Dates
First Submitted
January 21, 2026
First Submitted That Met QC Criteria
January 21, 2026
First Posted (Actual)
January 29, 2026
Study Record Updates
Last Update Posted (Actual)
January 29, 2026
Last Update Submitted That Met QC Criteria
January 21, 2026
Last Verified
January 1, 2026
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2025-12-01PS
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Choroid
-
Renmin Hospital of Wuhan UniversityRecruiting
-
Fondation Ophtalmologique Adolphe de RothschildCompleted
-
Medical University of GrazCompleted
-
The Second People's Hospital of FoshanNot yet recruiting
-
The Second People's Hospital of FoshanRecruiting
-
Shaare Zedek Medical CenterUnknownRetina, Choroid, Sclera
-
The First Affiliated Hospital with Nanjing Medical...Not yet recruiting
-
T.C. ORDU ÜNİVERSİTESİCompletedCataract | Choroid Disease | Epinephrine Toxicity | Carbachol Adverse ReactionTurkey
-
M.D. Anderson Cancer CenterTerminated
-
National Eye Institute (NEI)UnknownUveitis | Choroid Neoplasms
Clinical Trials on Oral glucose
-
Université de SherbrookeCanadian Diabetes AssociationCompleted
-
National Taiwan University HospitalCompleted
-
Loma Linda UniversityCompletedNeonatal Procedural PainUnited States
-
University Hospital, LilleCompletedDumping Syndrome | Oesophageal AtresiaFrance
-
Centre de Recherche en Nutrition Humaine Rhone-AlpeLESAFFRE SACompleted
-
Glostrup University Hospital, CopenhagenUnknown
-
Loma Linda UniversityCompletedPrevention of Procedural Pain | Reduction of Procedural Pain | Biochemical Effects of Oral DextroseUnited States
-
Ankara City Hospital BilkentRecruitingGestational Diabetes | Glucose Intolerance During PregnancyTurkey
-
Children's Hospital of PhiladelphiaCystic Fibrosis FoundationCompletedCystic Fibrosis | Cystic Fibrosis-related DiabetesUnited States
-
Christophe De BlockUnknownDiabetes Mellitus | Stress HyperglycemiaBelgium